Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Current Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Total Current Liabilities for 12 consecutive years, with $61.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 12.39% to $61.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.8 million, a 12.39% increase, with the full-year FY2025 number at $61.8 million, up 12.39% from a year prior.
  • Total Current Liabilities was $61.8 million for Q4 2025 at ImmunityBio, up from $57.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $613.5 million in Q2 2023 to a low of $49.2 million in Q1 2025.
  • A 5-year average of $184.7 million and a median of $68.1 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 460.52% in 2021, then crashed 90.48% in 2024.
  • ImmunityBio's Total Current Liabilities stood at $369.0 million in 2021, then surged by 35.74% to $500.9 million in 2022, then crashed by 88.36% to $58.3 million in 2023, then fell by 5.73% to $54.9 million in 2024, then grew by 12.39% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Total Current Liabilities are $61.8 million (Q4 2025), $57.1 million (Q3 2025), and $50.6 million (Q2 2025).